

Proposals ZEUS analyses and publications: July 2015.

Manuscript ZEUS is published in European Urology:

Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, **Witjes W**: Can zoledronic acid prevent bone metastases in high-risk non-metastatic prostate cancer patients ? Efficacy and safety results of the Zometa European Study (ZEUS). A prospective, randomized, open-label, multi-national study of the European Association of Urology (EAU) in co-operation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft für Urologische Onkologie (AUO). Eur Urol. 67: 482-491, 2015.

Focus on bone markers: Analysed by M. Lein and K. Miller. Clinical data have been sent in 2012. Draft is expected soon.

Anup Patel is interested in relation of timing of bone scan conversion to positive and bonemarker changes from negative to positive.

Focus on Bone scan analyses:

A. Bjartell: Bone Scan Index a new imaging biomarker for quantitative evaluation of treatment effects on bone metastases – An explorative side study based on the Zeus/SPCG11 study.

F. Lecouvet: draft manuscript central bonescan review after all FU information is received at the end of 2013.

Focus on DEXA scan analyses (Andrea Tubaro):

DEXA scan results and draft manuscript (?)

Possibility of interaction between ZA use and Gleason score/androgen suppression therapy (Denham RADAR trial, published 2014, Lancet Oncology)

Focus on PSA (Anup Patel):

Time to PSA doubling as depicted in the protocol / PSA progression events stratified between hormonally treated (ADT) and not hormonally treated patients.

Correlation between Bone scan progression and PSA doubling time stratified between 1) patients who underwent RP or RT versus those who did not receive treatment with a curative intent 2) patients on early ADT versus those not receiving early ADT.

Focus on important prognostic factors: Gleason, Lymphnode positivity, PSA > 20 ng, other prognostic factors like surgery/radiotherapy Y/N, hormonally treated Y/N and country of origin. Possible to validate a nomogram ?

A. Patel is interested in differences between countries and prescription of early ADT and timing of start of MAB.

T. Tammela is interested in manuscript to determine country differences and outcome of PCa.

T. de Reijke is interested to look at PSA, Gleason, PSA doubling time and outcome of treatment and the timing of second line treatment between two treatment arms.